RxDoctor Payments Data

John Sarkaria, MD

Pediatrics · Tustin, CANPI 1245250695

Payments from drug & device makers

$603in general payments, 2019–2025

Across 23 payments — averaging $26.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$222
  • Lilly USA, LLC$75
  • Exact Sciences$67
  • AbbVie$58
  • Novo Nordisk$43
  • AstraZeneca$31
  • plus $108 from 6 others

What the payments were for

  • Speaking & faculty fees$19933%
  • Food & beverage$40567%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$603 in reported general payments places this provider in the 75th percentile of 5,539 pediatrics providers in California.

See all pediatrics providers in California

Medicare billing

Part B allowed, 2024
$59,399
Medicare patients
161
Services billed
602

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide60$78,706
EliquisApixaban53$63,545
FarxigaDapagliflozin Propanediol40$44,087
JanuviaSitagliptin Phosphate25$31,630
TrulicityDulaglutide20$30,478
EmsamSelegiline13$27,337
JardianceEmpagliflozin25$23,808
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$21,650
EntrestoSacubitril/Valsartan11$14,353
SymbicortBudesonide/Formoterol Fumarate17$6,309
Atorvastatin Calcium571$5,125
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$4,511
Fluticasone-Salmeterol HfaFluticasone Propion/Salmeterol12$3,341
Famotidine147$2,595
Levothyroxine Sodium182$2,407

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$43$78,70660 claims
PfizerEliquis$17$63,54553 claims
AstraZenecaFarxiga, Symbicort$31$50,39657 claims
MerckJanuvia$12$31,63025 claims
Lilly USA, LLCTrulicity$75$30,47820 claims
GSKTrelegy Ellipta$222$21,65024 claims
AbbVieSynthroid$58$1,54919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,539 pediatrics providers in California.

Other pediatrics in Tustin

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →